Bo Zhai

Dr. Bo Zhai


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022
Verified
Journal Article
Closed access
ZWZongwen Wang
Zongwen Wang
QZQiankun Zhu
Qiankun Zhu
XLXiaodong Li
Xiaodong Li
XRXiaohang Ren
Xiaohang Ren
JLJingtao Li
Jingtao Li
BZBo Zhai
Bo Zhai

16 November 2020 in Aging
Verified
Journal Article
Open access
QZQiankun Zhu
Qiankun Zhu
HRHaiyang Ren
Haiyang Ren
XLXiaodong Li
Xiaodong Li
BQBo Qian
Bo Qian
SFShengjie Fan
Shengjie Fan
BZBo Zhai
Bo Zhai
For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can reverse resistance to sorafenib. We used bioinformatics methods to identify genes whose expression was differentially induced by sorafenib and regorafenib in HCC. We identified KIF14 as an oncogene involved in the acquired resistance to sorafenib in HCC and investigated its potential as a target for reversing this resistance. Sustained exposure of resistant HCC cells to sorafenib activated the AKT pathway, which in turn upregulated KIF14 expression by increasing expression of the transcription factor ETS1. Silencing KIF14 reversed the acquired resistance to sorafenib by inhibiting AKT activation and downregulating ETS1 expression by blocking the AKT-ETS1-KIF14 positive feedback loop. Moreover, injection of siKIF14 with sorafenib suppressed growth of sorafenib-resistant HCC tumors in mice. These results demonstrate that targeting KIF14 could be an effective means of reversing sorafenib failure or strengthening sorafenib's antitumor effects.

30 October 2019 in RSC Advances
Verified
Journal Article
Open access
PDF file
FHFengli Hu
Fengli Hu
DYDongdong Yang
Dongdong Yang
BQBo Qian
Bo Qian
SFShengjie Fan
Shengjie Fan
QZQiankun Zhu
Qiankun Zhu
BZBo Zhai
Bo Zhai
A notable liver ischemia/reperfusion (I/R) injury is observed during liver transplantation, shock, trauma and other systemic diseases. The main aim of the present study was to evaluate the fact that HMGB1 acts as an early mediator of inflammation in hepatic injury and the potential of the miR-449b-5p mimic in the restoration of liver disorders. Herein, a miR-449b-5p-loaded spermidine/PLGA nanoparticle system was successfully formulated to improve the systemic delivery and performance of encapsulated miRNA. The major findings of the present study were as follows: (i) the HMGB1 levels were elevated upon the occurrence of I/R in vitro and in vivo; (ii) the inhibition of HMGB1 prevented the spread of inflammation; (iii) miR-449b-5p (PN-miR mimic) increased the cell viability of hepatic cells and decreased cell apoptosis; and (iv) the protective ability of the PN-miR mimic was attributed to the inhibition of the pNF-κB and p-p65 pathways. Compared to the case of the I/R group, the serum AST and ALT levels were significantly reduced in the group treated with miR-449b-5p (PN-miR mimic), indicating the extent of reduction in liver inflammation. The present study highlighted the importance of miR-449b-5p in the treatment of hepatic injury and could serve as a guide to effectively attenuate liver disorders. The application of the proposed nanoparticle system in the systemic delivery of miR-449b-5p further enhances the prospect of this treatment strategy.

18 December 2024 in Cancer Letters
Verified
Journal Article
Closed access
JLJingtao Li
Jingtao Li
GZGuocai Zhong
Guocai Zhong
FHFengli Hu
Fengli Hu
YZYingnan Zhang
Yingnan Zhang
XRXiaohang Ren
Xiaohang Ren
BZBo Zhai
Bo Zhai

1 January 2023 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
SZShicong Zeng
Shicong Zeng
ZWZongwen Wang
Zongwen Wang
QZQiankun Zhu
Qiankun Zhu
XLXiaodong Li
Xiaodong Li
HRHaiyang Ren
Haiyang Ren
BZBo Zhai
Bo Zhai
Original Article Identification of risk and prognostic factors for intrahepatic vascular invasion in patients with hepatocellular carcinoma: a population-based study Shicong Zeng, Zongwen Wang, Qiankun Zhu, Xiaodong Li, Haiyang Ren, Bo Qian, Fengli Hu, Lishan Xu, Bo Zhai

3 July 2023 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
SZShicong Zeng
Shicong Zeng
YZYao Zhang
Yao Zhang
ZWZongwen Wang
Zongwen Wang
XRXiaohang Ren
Xiaohang Ren
JLJingtao Li
Jingtao Li
BZBo Zhai
Bo Zhai
In this study, we aimed to compare survival outcomes after receiving radiofrequency ablation (RFA) and hepatic resection (HR) for solitary hepatocellular carcinoma (HCC) with stratification by tumor size and age. A retrospective cohort was obtained from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015. Patients were grouped by tumor size (0-2, 2-5, and > 5 cm) and age (>65 and ≤65). Overall survival (OS) and disease-specific survival (DSS) were assessed. For patients >65 with tumors measuring 0-2 and 2-5 cm, the HR group had better OS and DSS compared with the RFA group. For patients >65 with tumors > 5 cm, OS and DSS did not differ significantly between the RFA and HR groups (p = 0.262 and p = 0.129, respectively). For patients ≤65, the HR group had better OS and DSS compared with the RFA group regardless of tumor size. For patients with resectable solitary HCC, regardless of age, HR is the better choice not only for tumors ≤ 2 cm, but also for tumors 2-5 cm. For resectable solitary HCC with tumors >5 cm, HR is the better choice for patients ≤65 but for patients >65, the issue of treatment choice needs to be further studied.